Galiximab Explained

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma.[1], it is undergoing Phase III clinical trials.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[3]

External links

Notes and References

  1. Book: Ebadi M, Sadeghi MA, Reddy NM, Rezaei N . Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma . https://books.google.com/books?id=v5AOEAAAQBAJ&dq=Galiximab&pg=PA178 . 178 . Rezaei M. Cancer immunology: cancer immunotherapy for organ-specific tumors . 2020 . Cham . Springer Nature . 978-3-03-057949-4 . Second.
  2. Web site: Biogen Idec: Pipeline . 2009-09-24 . https://web.archive.org/web/20080517130617/http://www.biogenidec.com/site/pipeline.html . 2008-05-17 . dead .
  3. https://web.archive.org/web/20091016222527/http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf WHO Drug Information

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Galiximab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.